Genzyme - PDFSEARCH.IO - Document Search Engine

Genzyme
Results: 158

#	Item
111	Genzyme Corporation 500 Kendall Street Cambridge, MA[removed]T[removed]November 11, 2009 Add to Reading List Source URL: www.fda.gov Language: English Genzyme Sanofi
112	Genzyme Corporation 500 Kendall Street Cambridge, MA[removed]T[removed]November 11, 2009 Add to Reading List Source URL: www.fda.gov Language: English Unit operations Orphan drugs Genzyme Sanofi Imiglucerase Alglucosidase alfa Respirator Syringe filter Alpha-galactosidase Chemistry Pollution Technology
113	HIG H LIG H TS O F PRES CRIBING INFO RMATIO N Th e s e hig hlig hts do n ot include a ll the information needed to u se MYO ZYME s afe ly and effectively . See full prescribing i nformation for MYO ZYME. MYO ZYME® (a l Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2014-05-27 14:10:42 Glycogen storage disease type II Genzyme Allergy Medicine Health Alglucosidase alfa
114	N020862 PREA Response[removed]) Add to Reading List Source URL: www.fda.gov Language: English Food and Drug Administration Pharmacology Therapeutics United States Public Health Service Genzyme Medicinal chemistry Pharmaceutical sciences Clinical research Clinical pharmacology
115	FOR IMMEDIATE RELEASE Jan van Heek Nominated to Supervisory Board of to-BBB Leiden, the Netherlands, 13 January 2014 – to-BBB, a biotechnology company that develops novel treatments for devastating brain disorders, has Add to Reading List Source URL: www.tobbb.com Language: English - Date: 2014-01-13 04:39:19 Pharmacokinetics Genzyme X Biology Pharmaceutics Pharmaceutical sciences Neurology Animal physiology Blood–brain barrier
116	risk-management-plan.pdf Page 1 of 10 Lumizyme® (alglucosidase alfa[removed]Risk Evaluation and Mitigation Strategy (REMS) Initial REMS Approval: [removed]Most Recent Modification: [removed] Add to Reading List Source URL: www.fda.gov Language: English Glycogen storage disease type II Hepatology Alglucosidase alfa Genzyme Pharmacist Medicine Health Rare diseases
117	Summary ICORD ACCORD workshops with ICORD’s different stakeholders ICORD Meets Industry June 18, 2014, Karolinska University Hospital, Stockholm, Sweden ICORD is a global organization, in which all stakeholders withi Add to Reading List Source URL: icord.se Language: English - Date: 2014-07-06 16:48:02 Orphan drug BioMarin Pharmaceutical Karolinska Institutet Pharmaceutical industry Karolinska University Hospital Genzyme Technology Health Epidemiology Rare disease
118	Sanofi-aventis: Acquiring Genzyme1 So-called “orphan drugs” target rare illnesses. While the demand for an orphan drug is relatively small, sales can be highly profitable. Founded in 1981, Genzyme applies biotechnolo Add to Reading List Source URL: www.comp.nus.edu.sg Language: English - Date: 2013-03-14 20:41:28 Imiglucerase Pharmaceutical industry Pharmacology Sanofi Genzyme Pharmaceutical sciences
119	BioMarin is currently seeking patients for a Phase 3 clinical trial in Late Onset Pompe Disease. This phase 3 study incorporates a switchover design in which all patients switch directly from Myozyme® or Lumizyme® 1to Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2014-06-16 18:19:57 Glycogen storage disease type II Hepatology BioMarin Pharmaceutical Sanofi Alglucosidase alfa Genzyme Clinical trial ClinicalTrials.gov Medicine Health Science
120	CFA Members GenzymeShortage Add to Reading List Source URL: www.fabrycanada.com Language: English - Date: 2012-02-26 16:46:11 Fabry disease Alpha-galactosidase Genzyme Enzyme replacement therapy Amyotrophic lateral sclerosis Rare diseases Health Lipid storage disorders

UPDATE